Childhood OverweightNCT04661449
Effects of Lifestyle Intervention on Childhood Outcomes in LGA Infants
A study testing Comprehensive lifestyle intervention in people with Childhood Overweight, run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine at 1 site in China.
Trial summary
Large-for-gestational-age (LGA) infants have a higher risk of metabolic disease later in life, and their postnatal growth in early childhood may be associated with long-term adverse outcomes. Read more about this study
- Who is it for?
- Ages 1 day to 1 month
- Conditions the study is for
- Childhood Overweight
- What is being tested?
- Comprehensive lifestyle intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 138 participants
- Where
- 1 siteChina
- Study dates
- 22 Jan 2021to 30 Nov 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 1 month
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- term
- large-for-gestational-age infants
Who cannot join
- major genetic disorder
- congenital anomalies
- severe digestive disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Xinhua Hospital
Shanghai, Shanghai Municipality, 2000892
Hongping Xia, Dr, 86-21-25078999 ext. 8392, xiahongping@xinhuamed.com.cn
About this study
Official title: Childhood Health Outcomes in Term, Large-for-gestational-age Infants: Effects of Lifestyle Intervention in the Postnatal First Year
Large-for-gestational-age (LGA) infants have a higher risk of metabolic disease later in life, and their postnatal growth in early childhood may be associated with long-term adverse outcomes. The purpose of this study is to explore whether comprehensive lifestyle intervention in the first year after birth in LGA infants will reduce the rate of overweight/obesity at childhood and improve neurodevelopmental outcomes and its possible mechanism.
Read the detailed description
Term LGA infants will be randomly divided into two groups shortly after birth: intervention group and control group. Infants in intervention group will attend the follow-up clinic and motor development assessment and guidance will be provided every three months in the first year. Other lifestyle interventions include feeding guidance and healthcare education. Infants in control group will routinely attend the follow-up clinic every six months. Primary outcome is the rate of overweight/obesity at two years old and seven years old. Neurodevelopmental assessment, carotid intima-media thickness (CIMT) and blood pressure at childhood will also be evaluated. The association of the outcome of LGA infants at two years old and the biomarkers in cord blood will be investigated, which includes serum leptin, insulin, insulin-like growth factors -1 (IGF-1), blood lipid series and adiponectin.
- Conditions
- Childhood Overweight
- Being tested
- Comprehensive lifestyle intervention
- Keywords
- large for gestational age
- Medical subject headings
- Pediatric Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive lifestyle interventionOther
Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
| Study group | Role | What they receive |
|---|---|---|
| Lifestyle Intervention | Experimental | every 3 months within 1 year. Receives: Other: Comprehensive lifestyle intervention |
| control group | No intervention | Regular follow-up every 6 months within 1 year. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of overweight/obesity at 2 years old
Weight and height will be combined to report BMI in kg/m^2. According to the intergrowth-21st age-specific BMI standard issued in 2014, BMI ≥ 85th percentile is defined as overweight; BMI ≥ 95th percentile is defined as obesity
Measured: at 2 years old
Rate of overweight/obesity at 7 years old
Weight and height will be combined to report BMI in kg/m^2. According to the intergrowth-21st age-specific BMI standard issued in 2014, BMI ≥ 85th percentile is defined as overweight; BMI ≥ 95th percentile is defined as obesity
Measured: at 7 years old
Secondary outcomes (6)
Neurodevelopmental assessment at 2 years old
Bayley III's assessment of infants is divided into five areas: cognition, language, body movement, social emotion and adaptive behavior.
Measured: at 2 years old
Carotid intima-media thickness (CIMT) at 2 years old
Carotid intima-media thickness (CIMT) will be measured by experienced Pediatric Cardiologist.
Measured: at 2 years old
Association of BMI at 2 years old with biomarkers in cord blood
Biomarkers include: serum leptin, insulin, IGF - Ⅰ, blood lipid series, adiponectin
Measured: at 2 years old
Association of BMI at 7 years old with biomarkers in cord blood
Biomarkers include: serum leptin, insulin, IGF - Ⅰ, blood lipid series, adiponectin
Measured: at 7 years old
Blood pressure at 7 years old
Blood pressure will be measured by experienced nurses.
Measured: at 7 years old
Carotid intima-media thickness (CIMT) at 7 years old
Carotid intima-media thickness (CIMT) will be measured by experienced Pediatric Cardiologist.
Measured: at 7 years old
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2020
- Study start22 Jan 2021
- Primary completion30 Nov 2023 (estimated)
- Study completion30 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Childhood OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized controlled trial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 138 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04661449
- Sponsor's protocol ID
- XH-20-023
- Status last verified
- Dec 2020
- First submitted
- 1 Nov 2020
- Last updated
- 5 Feb 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No